Clinical Trial Update: PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study

View source ↗

Summary

European post-approval surveillance study of the PROMUS Element everolimus-eluting coronary stent system has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• PROMUS Element Everolimus-Eluting Coronary Stent System (everolimus-eluting coronary stent system)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Coronary Heart Disease | Status: COMPLETED